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The advent of genomics and proteomics has been a catalyst for the discovery of biomarkers able to discriminate biological
processes such as the pathogenesis of complex diseases. Prompt detection of prion diseases is particularly desirable given their
transmissibility, which is responsible for a number of human health risks stemming from exogenous sources of prion protein.
Diagnosis relies on the ability to detect the biomarker PrP
Sc, a pathological isoform of the host protein PrP
C, which is an essential
component of the infectious prion. Immunochemical detection of PrP
Sc is speciﬁc and sensitive enough for antemortem testing of
brain tissue, however, this is not the case in accessible biological ﬂuids or for the detection of recently identiﬁed novel prions with
unique biochemical properties. A complementary approach to the detection of PrP
Sc itself is to identify alternative, “surrogate”
gene or protein biomarkers indicative of disease. Biomarkers are also useful to track the progress of disease, especially important
in the assessment of therapies, or to identify individuals “at risk”. In this review we provide perspective on current progress and
pitfalls in the use of “omics” technologies to screen body ﬂuids and tissues for biomarker discovery in prion diseases.
1.Introduction
Prion diseases, or Transmissible Spongiform Encephalop-
athies (TSEs), are invariably fatal neurodegenerative diseases
associated with the conversion of the normal host cellular
prion protein (PrPc) into the abnormal protease-resistant
isoform (PrPSc)[ 1]. They occur in a wide range of host
species including humans, the most common of which is
sporadic CJD (sCJD), occurring at a rate of approximately
1 case per million a year worldwide and accounts for
greater than 80% of CJD cases [2]. Amino acid changes,
which include point or insertional mutations in the normal
(cellular) prion protein (PrPC) encoded by the PRNP gene,
are linked to genetic prion diseases such as Gerstmann-
Strausler-Sheinker (GSS) disease, fatal familial insomnia
(FFI), and genetically associated Creutzfeldt-Jakob disease
(CJD). Acquired forms of disease are caused by ingestion of,
or exposure to, contaminated biological material via food or
during medical procedures. Kuru, found amongst the Fore
tribe in Papua-New Guinea, was the ﬁrst known human
transmissible spongiform encephalopathy and resulted from
exposure to infected material during ritualistic cannibalism.
More recently a new human prion disease has emerged,
variant CJD (vCJD), which is associated with exposure to
the BSE agent in beef. Cases of iatrogenic transmission
have also occurred through the use of improperly sterilized
surgical instruments, the use of human growth hormone
derived from cadaveric pituitaries, and transplantation of
corneas and dura mater from infected patients [3]. Recently,
human-to-human transmission of vCJD has been reported
through blood transfusion [4]; human-adapted prions are
more readily transmitted from human to human via this
route than via ingestion of BSE prions from contaminated
meat products [5].
Animals aﬀected by TSEs include sheep (Scrapie), cattle
(BSE) and mule, deer, elk (CWD). The impact of animal
TSEs is twofold; ﬁrstly, there is a risk of transmission to
humans, and secondly, the economic impact on animal
production has been substantial. Although scrapie has been
endemic for hundreds of years in many parts of the world its
transmission to humans has never been reported. However,
when vCJD in humans was determined to be associated with
consumption of contaminated food there was concern as to
what extent the population has been exposed. In the recent2 Journal of Biomedicine and Biotechnology
years, the incidence of CWD has increased markedly within
North America and although it has not been linked to
CJD either epidemiologically, or by laboratory conﬁrmation,
there is concern about the possibility for cross-species
transmission [6, 7]. TSEs in animals have caused huge
economic loses. Since the BSE epidemic began in 1986,
millions of cattle have been slaughtered and bans on the
importation of beef have aﬀected many countries and cost
billions of dollars.
The threat posed to public health by dietary and medical
exposure to prions has driven tremendous eﬀorts to develop
sensitivemethodsofdetectionofprionstocontrolthespread
of human and animal TSEs. All the commercially available
diagnostic tests for TSEs rely on the direct detection of the
proteinase K resistant, misfolded form (PrPSc)o fc e l l u l a r
prion proteininthecentralnervoussystem(CNS).Although
methodologies are sensitive and speciﬁc for postmortem
diagnosis, the use of PrPSc as a preclinical or general
biomarker for surveillance is diﬃcult, due to the fact that it
is present in extremely small amounts in accessible tissues or
body ﬂuids such as blood, urine, saliva, and cerebrospinal
ﬂuid (CSF). Recently, ampliﬁcation techniques have been
developed which have enabled increased sensitivity. These
are based on the ability of the disease-related abnormal
isoform, PrPSc, to convert a pool of normal PrPC to a
proteinase K resistant form thus “amplifying” the original
infectious seed. Ampliﬁcation can be increased by breaking
down the resulting aggregated seeds of PrPSc to smaller units
which in turn act as seeds for further replication until levels
of PrPSc detectable by Western blot or ELISA are produced.
These developments may provide the sensitivity necessary
for a blood or food screening test useful for some of the
transmissible TSEs. However, it has recently been reported
that proteinase K sensitive, pathological isoforms of PrP may
have a signiﬁcant role in the pathogenesis of some prion
diseases [8]. Novel PrPSc isoforms with unique biochemical
properties may be generated in sporadic or acquired disease
that exhibit increased sensitivity to PK digestion. Therefore,
conventional tests may show signiﬁcant discordance between
the amounts of PrPSc detected and the infectivity observed.
Accordingly, the development of new diagnostic tests that
do not rely on PK digestion is desirable. Another challenge
for diagnosis and surveillance is that hosts can incubate
infectious prion agents for many months or years, during
which time they exhibit no overt symptoms. Incubation
periods for some human prion diseases can be as long as
40 years and given the recent cases of vCJD transmitted by
blood transfusion the need for development of a test for
screening blood has increased. Furthermore, a noninvasive
test to identify the early stages of CJD would be valuable in
the development of treatment strategies for TSEs.
A biomarker is deﬁned as a discriminative feature that
can be measured objectively and used as an indicator
of biological processes such as normal health, pathogenic
processes, or pharmacological responses to a therapeutic
treatment. Biomarkers include physical traits such as tem-
perature or blood pressure, imaging of pathological features
such as amyloid deposition or ventricular volume changes
in the brain, and the presence of biological molecules
in tissues and body ﬂuids such as blood or urine. One
aim of biomarker discovery is the detection of molecular
correlates of disease that can be used as early diagnostic
tools. However, this type of marker has a crucial requirement
for high sensitivity and speciﬁcity. Few markers of this
type have emerged from omics studies, not only for prion
diseases but also for the multitude of other diseases that
have been investigated. Biomarkers with broad speciﬁcity for
neurodegeneration (not only in TSEs) may also be useful
as general indicators of disease pathology; identiﬁcation
of biomarkers to follow the progression of disease would
signiﬁcantly impact the time and cost required to evaluate
the eﬃcacy of therapeutic interventions.
The search for biomarkers (other than PrPSc)a st o o l s
for diagnosis of prion diseases has a long history; in fact
thereareseveralproteinmarkersincerebrospinalﬂuid(CSF)
that are useful for diagnosis of human prion diseases. In
1980, two proteins were identiﬁed by 2D electrophoresis in
the CSF of sporadic CJD patients. One of these, a 30kDa
polypeptide, was identiﬁed as a member of the 14-3-3 family
of proteins, a normal neuronal protein that is released into
the CSF after neuronal insult. The CSF detection of 14-
3-3 protein by Western blot is widely used as diagnostic
evidence of CJD, in conjunction with clinical indicators of
prion disease [9]. The detection of 14-3-3 in CSF is a highly
sensitivemarkerforsCJD,iCJD,andthegeneticformofCJD,
however, is much less sensitive for diagnosis of vCJD, GSS,
and FFI [10]. A number of other proteins are also increased
in the CSF of CJD patients including Tau and phospho-
Tau, S-100ß, and neuron-speciﬁc enolase (NSE). Levels of
the tau protein are raised in patients aﬀected by all forms
of CJD including vCJD. A recent study determined that the
detectionoftauinCSFhasasensitivityof80%andspeciﬁcity
of 94% for vCJD, higher than any of the other markers
tested. Testing for the presence of multiple markers, 14-3-
3 protein in CSF plus tau, results in the highest sensitivity
for the use of these biomarkers in diagnosis of human TSEs
[11]. These CSF biomarkers have proven to be extremely
useful in conﬁrmatory diagnostics of CJD cases, and their
widespread use illustrates an important role for surrogate
marker detection in prion disease. They do not, however,
have comprehensive value for surveillance of transmitted
TSEs and are useful only when the disease is already at an
advanced state. Ideally biomarkers able to detect all TSEs
even at preclinical stages of infection are desirable. This
paper will focus on recent eﬀorts to harness the plethora of
omic technologies to identify not only potentially diagnostic
biomarkers,butalsomarkerstofollowdiseaseprogressionor
which have risk determining potential.
2. Tools for Biomarker Identiﬁcation in TSEs
In the last few years technologies to study all the genes and
proteins expressed in an organism or cells simultaneously
have become accessible for most laboratories, and these
provide a platform for biomarker discovery. Experimental
strategiestodetectbiomarkersgenerallyinvolvecomparisons
of mRNA, protein, peptide, and metabolite abundancesJournal of Biomedicine and Biotechnology 3
between samples collected from infected versus control
tissues. The most commonly used technologies are described
here, followed by discussion of approaches that are being
used in the identiﬁcation of useful biomarkers in relation
to prion disease, as well as potential directions for future
research.
2.1. Diﬀerentially Expressed mRNA Biomarkers. High-
throughput genomic techniques, most commonly DNA
microarrays and subtractive hybridization approaches,
are the most frequently reported methodologies used
for the identiﬁcation of deregulated genes in tissues and
cells [12]. These expression proﬁles, or “signatures,” can
themselves be used grossly as biomarkers, are relatively
easy to generate, and the techniques can be readily adapted
to high throughput. Signatures can be compared across
multiple time points, tissues, or experimental populations to
look for molecules predictive of disease. With the advent of
ultra-high-throughput sequencing technologies, researchers
are increasingly turning to deep sequencing for gene
expression studies [13–15]. Advantages over microarray
approaches are that diﬀerent variants or “isoforms” of
mRNA generated by diﬀerential splicing, alternative
termination, and alternative transcriptional start sites are all
identiﬁed. Additionally, these methodologies are also well
suited for the identiﬁcation and proﬁling of small RNAs,
such as miRNAs, which are increasingly thought to play
important roles in neurodegenerative diseases and may be
useful biomarkers [16]. One recent innovation that has been
applied to high-throughput sequencing is the puriﬁcation
of RNA from ribosome complexes prior to deep sequencing
to capture those templates actively undergoing translation.
T h i sm e t h o dh a sb e e nf o u n dt ob em o r er e ﬂ e c t i v eo fp r o t e i n
abundance than are traditional microarray or sequenced
mRNA proﬁles and may improve the ability to infer protein
biomarkers from RNA proﬁles [17].
Changes in mRNA proﬁles in brain tissue from CJD
patients are infrequently studied due to the rarity of cases.
Only one report has been published using tissues isolated
from the postmortem brain samples of sporadic CJD
patients; transcriptional changes pointed to alterations in
neuronal dysfunction pathways including the cell cycle, cell
death, and the stress response [18]. A number of genomic
analyses of brain tissue from rodent adapted models of
prion diseases including CJD, scrapie and BSE have been
performed, as well as investigation of samples from larger
animals, sheep infected with scrapie and cattle infected
with BSE [19–27]. These studies have revealed widespread
alterations of multiple cellular pathways correlating with
the onset of pathological disease including cholesterol
homeostasis, ion homeostasis, and regulation of apoptosis,
stress response, and metal ion homeostasis. The most
consistent ﬁnding between experimental models, relates to
the onset of neuroinﬂammation, a process common to many
neurodegenerative diseases that is likely induced by damage
and death of neurons. Accordingly, many of these transcrip-
tional changes have been consistently identiﬁed in multiple
neurodegenerative diseases and a selection of these is listed
in Table 1. Although diﬀerential expression of these genes
may not be speciﬁc to prion diseases, neuroinﬂammation-
related gene expression may be an excellent choice as
candidate biomarkers to track the stage of development of
the neurodegenerative process and to predict the response to
therapy.
Studies to correlate the temporal changes in neuronal
health during disease have not yet been reported in prion-
infected neurons; however, hippocampal neurons from
Alzheimer’s disease (AD) patients have revealed a tran-
scriptional response comprising thousands of genes that
signiﬁcantly correlates with AD markers [31, 32]. It is
possiblethatatleastinpart,thesebiologicalprocessesmaybe
common to degenerating neurons in multiple degenerative
conditions. In this casethese biomarkers may well be broadly
applicable to track the progression of neurodegeneration.
As the vast majority of human samples are collected post-
mortem, animal models may be the only practical way of
assessing early markers of neuronal status prior to obvious
clinical symptoms. A number of studies have attempted
to use genomics to determine transcriptional changes at
preclinical stages of disease; however, due to the cellular
complexity of brain tissue only modest fold changes are
revealed. Subtle alterations occurring in a small number of
neurons at the onset of disease are likely masked. To get
the best results from this type of study it is essential to
use large sample numbers for statistical signiﬁcance. Neuron
speciﬁc expression changes may be masked even at late
stages of disease by the extensive astrocytosis and gliosis that
accompany neuronal degeneration. Neurons, and therefore
their genetic material, are outnumbered 10 or 20 to 1. Laser
capture microdissection to excise speciﬁc cell populations
is set to overcome many of the limitations of whole tissue
analysis and will undoubtedly provide a new “layer” of
information regarding speciﬁc cellular responses to prion
replication.
2.2. Diﬀerentially Expressed Protein Biomarkers. Protein
biomarkers are particularly well suited for measuring and
detecting phenotypic characteristics of disease processes.
Proteomic technologies enable the exhaustive analysis of the
protein content of a tissue or bodily ﬂuid sample. Only
in the recent years has technological advances facilitated
the diﬀerential measurement of protein abundance levels
between multiple conditions at a given time, and just as
importantly, provided suﬃcient “through-put” to attach
statistical signiﬁcance to protein biomarker detection. Pro-
teomics of prion infected tissues also suﬀer from some of
the same drawbacks of genomics studies; samples are often
very heterogeneous due to cellular complexity and the stage
of disease. One of the major caveats of proteomics for
prion disease discovery is that the commonly used rodent
models provide very small sample volumes, especially in
terms of bodily ﬂuids such as blood, from which only the
most abundant proteins can be identiﬁed. The laser capture
microdissection techniques hold much promise for genomic
studies to reduce cell heterogeneity as the small amounts of
nucleic acid can be ampliﬁed by polymerase chain reaction4 Journal of Biomedicine and Biotechnology
Table 1: Genes with diﬀerential abundances in prion disease and other neurodegenerative disorders.
Gene Description Reference for
Prion Disease Other Neurodegenerative Disorder∗
ABCA1 ATP-binding cassette, subfamily A (ABC1),
member 1 [20, 22, 23]A D
APLP1 Amyloid beta (A4) precursor-like protein 1 [20]A D
APOD Apolipoprotein D [20, 20, 23, 25, 28]A D , N P C
APOE Apolipoprotein E [20, 22, 25]A D , P D a n d M T S
B2M Beta-2-microglobulin [20, 22, 25, 29] AD, Tay-Sachs, Sandhoﬀ disease, and MTS
CD9 CD9 molecule [20, 22, 23, 25] SSPE, CMT
CLU Clusterin [20, 25, 30]A D , P D
CST3 Cystatin C (amyloid angiopathy and cerebral
hemorrhage) [20, 25, 30]A D , M T S
CTSB Cathepsin B [20, 22, 25] AD, Seizures, Tay-Sachs, and Sandhoﬀ disease
CTSS Cathepsin S [20, 22, 23, 25, 28]A D
GFAP Glial ﬁbrillary acidic protein [20, 22, 23, 25, 28] Tay-Sachs, Sandhoﬀ disease, MTS, and AD
SPARC Secreted protein, acidic, cysteine-rich
(osteonectin) [20] Tay-Sachs, Sandhoﬀ disease, and MTS
SPP1 Secreted phosphoprotein 1 (osteopontin, bone
sialoprotein I, early T-lymphocyte activation 1) [20, 22]P D
∗AD:Alzheimer’s Disease; PD:Parkinson’s Disease; NPC:Niemann-Pick type C; MTS:Mesial temporal sclerosis; SSPE:Subacute sclerosing panencephalitis,
CMT:Charcot-Marie-Tooth disease.
(PCR). However, proteins cannot be ampliﬁed and ultra-
sensitive techniques must be developed in order to perform
similarproteomicstudies.Newtechniquesforlabellingsmall
amounts of protein such as ﬂuorescence saturation labelling
may be one step in the right direction to overcome these
limitations. This technique has enabled proteomic analysis
of hippocampal CA1 neurons in an Alzheimer’s mouse
model; however identiﬁcation of such small amounts of
protein requires increased sensitivity of mass spectrometry
techniques [33]. Given these problems and the scarcity of
samplesfromlargeanimalmodelsandhumanTSEcases,itis
notsurprisingthatonlyaverysmallnumberofprion-related
proteomic studies have been reported. Table 2 provides a
general summary of these, and some examples from similar
studiesofneurodegenerative diseaseswithsimilaraetiologies
as proof of principle.
Current methodologies for proteomics follow two prin-
cipal steps. Firstly proteins are separated to provide a sample
withdecreasedcomplexityandthenmassspectrometry(MS)
is used for protein identiﬁcation. Separation techniques
include surface-enhanced laser desorption ionizing time
of ﬂight (SELDI-TOF), two-dimensional gel electrophore-
sis (2D-GE) and the recently developed two-dimensional
diﬀerential gel electrophoresis (2D-DIGE) for diﬀerential
protein analysis, and liquid chromatography (LC). All of
these methodologies are not inherently quantitative but have
been adapted to allow the user to identify qualitative changes
between samples, for example, diﬀerential abundances of
proteins between diseased and control tissues.
Surface-enhanced laser desorption ionizing time of ﬂight
(SELDI-TOF) is a mass spectrometry technique that is
based on a combination of techniques, chromatography, and
matrix-assisted laser desorption ionization time of ﬂight
(MALDI-TOF) [44]. In the ﬁrst step of SELDI-TOF MS
proteins are captured using diﬀerent platform chemistries
such as absorption, electrostatic interaction, and aﬃnity
chromatography which reduce the complexity of the original
sample. This happens on a small “protein-chip” surface
which enables multiple separations to be performed on very
smallsamplevolumesathighthroughput.Followingthis,the
bound proteins are cocrystallized with an energy absorbing
matrix(EAM)whichisthenvaporizedpropellingtheionized
proteins down the ﬂight tube through an electric ﬁeld
based upon the particles mass/charge (m/z) ratio. Contact
of complexes with the detector at the end of the ﬂight
tube results in a unique peak resolved by m/z ratio of the
original protein or protein isoform. The advantages of this
method are the ability to perform high-throughput analysis
of hundreds or thousands of samples, resolving power of the
captured proteins, and the ease of analysis using dedicated
user friendly software. However, protein peaks of interest
must be experimentally isolated for identiﬁcation using
peptide mass ﬁngerprinting along with protein puriﬁcation
techniques. This step requires much larger sample volumes
than used in the initial discovery stage and can be arduous
and time-consuming.
In 2D gel electrophoresis separation of proteins is
performedinapolyacrylamidegelaccordingtotheirsizeand
their charge thus enabling resolution of multiple isoforms
of an individual protein. The spot intensities can be used to
calculate diﬀerences in protein abundance between diﬀerent
samples and individual protein spots can then be excisedJournal of Biomedicine and Biotechnology 5
Table 2: Potential Biomarkers of Neurodegenerative Diseases Identiﬁed by Mass spectrometry (MS) and 2D-Gel Electrophoresis.
Marker Fluid Disease∗ Reference
10kDa subunit of vitronectin Serum AD [34, 35]
alpha 1-acid glycoprotein Serum AD [34, 35]
alpha1-antichymotrypsin Urine CJD [36]
Apolipoprotein B100 Serum AD [34, 35]
Apolipoprotein E Serum and CSF AD and PD [29, 34, 35]
Cathelicidin antimicrobial peptide (Bos taurus) Urine BSE [37]
Clusterin Urine, CSF, blood, and plasma BSE and AD [37–39]
Complement C3 component C3dg Serum ALS and PD [40]
Complement C3 components of C3c family Serum ALS, PD, and AD [34, 35, 40]
Complement C4 Serum AD [34, 35]
Complement Factor H Serum and Plasma ALS, PD, and AD [34, 35, 40, 41]
Fragment Bb of Complement Factor B Serum PD [40]
Haptoglobin α-2 chain Serum and CSF AD and PD [29, 34, 35]
Heart-type fatty acid binding protein (H-FABP) Plasma and CSF CJD and AD [42]
Hemoglobin α-2 chain Serum AD [34, 35]
Histidine-rich glycoprotein Serum AD [34, 35]
Ig Gamma-2 chain C region (Bos taurus) Urine BSE [37]
Transthyretin Serum and CSF CJD, AD, PD [29, 34, 35, 43]
Uroguanylin Urine BSE [37]
Vitronectin precursor Serum AD [34, 35]
α-2-macroglobulin (α-2M) Plasma and Serum AD [34, 35, 41]
∗AD:Alzheimer’s Disease; PD:Parkinson’s Disease; ALS:Amyotrophic lateral sclerosis.
from the gel and identiﬁed using MS. Practical issues
such as variations in sample preparation make it very
diﬃcult to get consistently reproducible gels making this
methodology labour intensive. Recent adaptations to this
methodology have improved the situation somewhat, with
the most signiﬁcant innovation being labelling of samples
using ﬂuorescence dyes (2D-DIGE). In this way it is possible
toincludethreesamplespergel,controlandinfectedsamples
plus an internal standard (pooled samples). This creates a
standard for each protein in the analysis resulting in the user
being able to make comparisons across diﬀerent gels with a
high degree of conﬁdence [45].
In LC the sample components interact to a varying
extent with a chromatographic packing material in a column
(stationary phase). A pump moves the mobile phase through
the column, and the sample is separated based on a retention
time through the column which varies depending on the
interactions between the stationary phase, the molecules
being analyzed, and the solvent used. Generally protein
samples are enzymatically digested prior to loading on the
column. This diﬀers from both SELDI and 2D-GE in which
it is generally intact proteins that are separated. In one
dimension the peptide mixtures are generally too complex
to separate; however, in combination with chromatography
or 2D gel electrophoresis the methodology provides a
means to perform large-scale proteomic analysis with good
dynamic range. Labelling of peptides with isotopes enables
this methodology to be used to identify the diﬀerential
abundance of peptides between samples. To do this a stable
isotope is used to label peptides. The labelled peptide is
chemically identical to its native counterpart, so it behaves
in an identical fashion during chromatographic separation,
however it is distinguishable by MS, therefore variation
in abundance between a tagged and untagged sample
can be determined. A number of approaches using this
methodology have been described including Isotope Coded
Aﬃnity Tagging (ICAT) and the recently described Isobaric
Tagging for Relative and Absolute Protein Quantiﬁcation
(iTRAQ) quantitative proteomic approach [46]. iTRAQ is
ideally suited for biomarker applications, as it provides both
quantiﬁcation and allows some degree of multiplexing in a
single reagent. The isotopic tag can be incorporated either
during sample labelling or in vivo (stable isotope labelling,
SILAC), further increasing its scope [47].
MS to identify the mass/charge ratio of the pep-
tide/protein of interest or to determine the primary sequence
of the peptide is the ﬁnal step in all proteomic approaches.
This step involves ionization of the sample; MALDI and
electrospray ionization (ESI) are the most commonly used
technologies for this. In MALDI the sample is mixed with
a matrix, applied to a target surface and inserted into a
vacuum chamber and a laser is used to activate sample
ionization. In ESI the sample is dissolved in a solvent and
pumped through a narrow, stainless steel capillary. A high6 Journal of Biomedicine and Biotechnology
voltage is applied to the tip of the capillary, which is situated
within the ionisation source of the mass spectrometer, and
as a consequence of this strong electric ﬁeld, the sample
emerging from the tip is dispersed into an aerosol of highly
charged droplets. A gas, usually nitrogen, helps this process
and directs the spray emerging from the capillary tip towards
the mass spectrometer. The ionized sample is generally
resolved based on the m/z ratio in a time-of-ﬂight (TOF)
analyser. However, a number of choices for ion sources are
available and these can be combined with diﬀerent spec-
trometers. One promising innovation is fourier transform
mass spectrometry (FTMS), a popular tool for discovery due
to its high resolving power, mass measurement accuracy,
multistage MS/MS potential, and extended dynamic range
[48].Whenaccompaniedby1Dor2Delectrophoresis,FTMS
has demonstrated an excellent ability to deal with sample
complexity for biomarker discovery [49].
One further innovative method sometimes used in
biomarker discovery is the antibody microarray, the pro-
teomic equivalent of gene microarrays. In these arrays
speciﬁc antibodies are spotted onto glass or membranes,
or bound to beads in ﬂuidic arrays. Target proteins are
then captured from samples of plasma or disrupted tissue
and detected using an ELISA type approach using labelled
secondary antibodies. The use of these arrays has not
been described in prion disease; however a study to screen
the abundance of 120 signalling proteins in plasma from
Alzheimer’s patients was recently reported. A total of 259
samples were analysed with the antibody panel, and 18
proteins were identiﬁed as potential biomarkers. These pro-
teins were used to classify blinded samples from Alzheimer’s
and control subjects with close to 90% accuracy as well
as identifying patients with mild cognitive impairment that
progressed to Alzheimer’s disease 2–6 years later. The 18
proteins are involved in biological processes known to be
disrupted in neurodegeneration including deregulation of
haematopoiesis, immune responses, apoptosis and neuronal
support [50].
3.Searching the Body for Prion
Related Biomarkers
Thecomplexityofprion-inducedneurodegenerativediseases
along with their unique molecular mechanisms poses huge
challenges to understand their biology and to identify
antemortem biomarkers. In addition the diseases are aeti-
ologically heterogeneous. Prion diseases are unique in that
they can occur in one of three ways, spontaneously, via
genetic changes, or acquired through oral or iatrogenic
transmission of the infectious agent. Spontaneous or genetic
forms of the disease arise and progress solely in the brain,
with minimal to no agent replication in the periphery. Only
in the case of a TSE transmitted by digestion or blood
transfusion, such as in vCJD, does the initial replication
of the agent take place in the periphery. Implications of
these aetiologies are that diagnostic biomarkers, especially
for preclinical stages of disease, will unlikely encompass all
forms of prion disease.
Prions acquired from diﬀerent sources, strains, or dif-
ferent genetic origins present with diﬀering symptoms,
incubation periods, and pathobiological features will result
in ambiguities in biomarker detection. Accordingly, the
tissues and bodily ﬂuids chosen for biomarker selection need
to be tailored to the TSE under study and the speciﬁc aim of
biomarker selection. For example, blood or lymphoid tissue
may be the sample of choice for selection of a preclinical
marker of vCJD infection, brain tissue for indicators of
prognosis, and blood or urine to follow disease progression
or perhaps to identify individuals more susceptible to disease
or particular treatments.
Whilespeciﬁcitytopriondiseasewouldbearequirement
for identifying preclinical cases or screening donated blood,
for example, progression of disease could be followed using
markers of broader speciﬁcity such as indicators of CNS
damage and neuronal death. To further complicate the
selection of biomarkers in prion disease the long incubation
period prior to development of clinical symptoms, from
many months to many years, may well result in temporal
diﬀerences in marker expression. Therefore disease stage, as
well as target tissue, needs to be taken into account when
deciding on a sampling strategy and evaluating biomarkers.
The greatest public health risk accompanies those TSEs that
can be transmitted in food, medical products, and blood
such as vCJD or any future novel outbreaks. A closer look
at prion pathogenesis in these instances may lead to the
identiﬁcation of appropriate tissues and body ﬂuids for early
detection of prion diseases. A summary of these potential
tissues and body ﬂuids is given in Figure 1(a).I nFigure 1(b)
a schema illustrating the incubation period of a typical
TSE indicating disease stages optimal for identiﬁcation of
biomarkers for diﬀerent purposes is provided. In the next
section we describe some of these tissues and bodily ﬂuids
that are potential reservoirs for biomarkers in more detail,
and review related biomarker studies.
3.1. Biomarkers in Lymphoid Tissues. Following ingestion of
contaminatedfoodstuﬀs,PrPSc mustbetransportedfromthe
gut to the brain. Current data suggests that PrPSc crosses
the gut epithelium, possibly through M cells, and rapidly
accumulates in the gut-associated lymphoid tissues (GALTs),
mainlyinthemesentericlymphnodes,andtheninthespleen
early in the preclinical phase prior to neuroinvasion. Two
studies of gene expression changes have been described using
tissue from infected and control Peyers patches. In the ﬁrst
samples from cattle orally infected with BSE revealed 90
genes and 16 ESTs to be diﬀerentially expressed. Of these
genes, ﬁve were found to be related to immune function.
These were major histocompatibility complex (MHC) class
II, MHC class II DQ alpha, L-RAP, and two hypothetical
proteins. Other diﬀerentially expressed genes identiﬁed
related to cellular and metabolic processes including the
development and maturation of cells [51]. In the second
study the mRNA level of a pancreatitis-associated protein
(PAP)-like protein was found to be elevated in the ileal
Peyer’s patch of lambs during the early phase of scrapie
infection [52]. Although the ﬁrst study tissue analysed wasJournal of Biomedicine and Biotechnology 7
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Figure 1: Summary of the tissues, cell populations, and bodily
ﬂuids that provide a source of discovery for biomarkers of prion
infection (a). Schema to illustrate the stage-speciﬁc diagnostic and
therapeutic windows for biomarker identiﬁcation for diagnosis,
disease progression, and monitoringpharmacological interventions
(b).
12 months following oral inoculation Peyers Patches may be
sources of very early disease speciﬁc markers.
I nBc e l lf o l l i c l e s ,P r P Sc is detected on follicular dendritic
cells (FDCs) networks and macrophages within germinal
centres (GCs) [53–55] of the spleen and lymph nodes.
Although prion infection still occurs in the absence of FDCs,
the infection is severely delayed suggesting that FDCs are
signiﬁcant cellular sites of peripheral replication [53, 56, 57].
The lymphoinvasion step is an appealing point in the disease
process for the identiﬁcation of biomarkers as it occurs prior
to neuroinvasion in those TSEs with ingestion aetiologies
and is thus the optimal time point for early diagnosis or
therapeutic intervention [58]. In addition lymphoid tissues
are also more accessible than brain tissue for sampling
purposes. Despite this, very few studies describing gene
or protein biomarkers associated with prion replication
in spleen or lymph nodes have been published. A recent
study has identiﬁed changes in the expression of St6gal1,
St3gal5, Man2a1, Hexb, Pigq, glycosylation-related genes, in
the spleens of scrapie infected mice [59]. The authors suggest
that this indicates modiﬁcation of the splenic metabolism of
glycosphingolipids associated with prion disease.
FDCs themselves express high levels of PrPC and are able
to retain antigens for relatively long periods of time, includ-
ing replicating PrPSc, making them good cell candidates for
the identiﬁcation of biomarkers. However, FDCs make up
lessthan1%ofthetotalcellswithinthespleenorlymphnode
which likely means that most disease associated expression
changes are masked when looking at whole tissues. They
are also tightly associated with other cell types, especially B
cells, which along with the gap in knowledge regarding their
lineage and molecular characteristics make them diﬃcult to
isolate for independent analysis. One study, however, has
shown an increase in clusterin expression in association with
abnormalPrPaccumulationexpressiononFDCsduringTSE
disease, particularly human vCJD cases [60].
Lymph ﬂuid passes through lymph nodes and contains
a mixture of proteins and antigens picked up from the
interstitialtissueswhichitdrains;itthereforereﬂectschanges
associated with any immunoinﬂammatory response within
the node itself. The protein composition therefore emulates
that of blood as well as being highly reﬂective of the
host response to mucosal challenge. Given the route of
transmission of acquired prion infections following inges-
tion and the subsequent preclinical replication in lymph
nodes, lymph ﬂuid may be an excellent, as yet untested
source, from which biomarkers that accompany preclinical
prion disease progression can be identiﬁed. In the human
genetic and sporadic forms of prion diseases, the disease
occurs spontaneously within brain tissue and there is no
preliminary involvement of peripheral tissues, and so FDCs
and macrophages do not play a role in disease pathogenesis.
Indeed PrPSc is most often absent in the lymphoid tissues,
although, secondary infection of lymph nodes can occur in
some instances, as recent studies show that PrPSc can be
detected in spleens of patients with sCJD [61]. Biomarkers
speciﬁcally expressed in lymphoid tissue or FDCs would
therefore be useful for the detection of TSEs acquired
speciﬁcally by peripheral exposure.
3.2. Biomarkers in CSF. Following neuroinvasion and estab-
lishment of prion disease in the brain of transmitted TSEs
and following the onset of sporadic or genetic forms of
disease, the CSF has been the tissue of choice for diagnosis
and biomarker identiﬁcation, due to its obvious association
withtheCNSandthefactthatitissomewhatmoreaccessible
than CNS tissue itself. CSF is ideal for use in protein and
gene expression proﬁling techniques to identify biomarkers
both to track progression of neurodegeneration, as well as
having the potential to contain biomarkers speciﬁc to prion
replication.
Studies using 2D gel electrophoresis to proﬁle proteins
in CSF have the longest history in biomarker identiﬁcation
for CJD. A number of studies have identiﬁed cystatin C,
transferrin, ubiquitin, Apoliprotein J, lactate dehydrogenase,
14-3-3 proteins plus other as yet unidentiﬁed polypep-
t i d e sa sp o t e n t i a lb i o m a r k e r s[ 43, 62, 63]. In addition
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a 13.4KDa protein. Further analysis using cationic exchange
chromatography, sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE), and liquid chromatography-
tandem mass spectrometry (LC-MS/MS) revealed this pro-
tein to be cystatin C. Immunoblotting conﬁrmed the signif-
icantly increased abundance of cystatin C in all eight CJD-
aﬀected patients included in this preliminary study [64].
Interestingly many, if not all, of the genes mentioned above
have also been identiﬁed as diﬀerentially expressed in brain
tissue of rodents infected with prions. A study by Brown et
al. also links the levels of diﬀerentially expressed genes to
protein levels in the CSF, an observation that suggests that
candidate gene panels identiﬁed from animal studies could
be used for prediction of disease-associated CSF biomarkers
[30, 65–67]. The detection of biomarkers in the CSF appears
promising; however, all of the above-mentioned proteins
have been observed to increase in abundance in the brains
and/or CSF in other neurodegenerative conditions such
as Alzheimer’s disease or in traumatic brain injury. This
ﬁnding suggests that the proteins identiﬁed to date are not
speciﬁc markers for prion disease but general biomarkers
of neurodegeneration disease or trauma. However, the use
patterns of expression of panels of these markers may confer
speciﬁcity, or alternatively, these markers could well be used
as useful indicators of disease progression.
Recently, a proof of principle study revealed that the
combination of MALDI-FTMS, in addition to machine
learning for the classiﬁcation of mass spectral features, is
abletoidentifypreclinicalproteinsignaturesfromtheCSFof
prion infected animals with reasonable predicative accuracy
[68]. In this study CSF was isolated from 21 infected and
22 control hamsters at a time-point when approximately
80% of the expected incubation period had been completed.
CSF was isolated and subjected to trypsin digestion with-
out further fractionation and subjected to MALDI-FTMS,
a methodology described earlier in the chapter. Peptide
proﬁles were identiﬁed and the peaks compared using
IonSpec peak picking software; a number of peptide peaks
exhibiting diﬀerential abundances were identiﬁed. It was
reported that these peaks were amongst the least abundant
peptides detected in the study, highlighting the need for
improved methodologies to target low abundance proteins
and peptides in biomarker studies. A linear support vector
machines (SVM) and 10-fold leave-one-out cross validation
was used to evaluate the predictive accuracy of the peptide
peaks showing the greatest diﬀerences in abundance between
infected and non-infected hamsters. The predictive accuracy
was determined to be 72%; true positive rate of 73% and
false positive rate of 27% using a 10-fold leave-one-out cross
validation demonstrated a potential for the use of proteomic
proﬁling of CSF for the identiﬁcation of multiple biomarkers
withdiagnosticvalue.However,theidentityofthesepeptides
was not resolved in this study. Although speciﬁcity was
fairly low, as mentioned by Herbst et al. a disease-speciﬁc
protein signature clearly exists in the CSF. This type of
approach combined with a prefractionation step to improve
the accuracy of biomarker detection in the range of low
abundance proteins could well result in identiﬁcation of a
panel of markers with diagnostic potential. In this case the
small size of hamsters and small volumes of CSF precludes
this approach so larger animal models or human samples
would be required. The comparison of protein proﬁles with
other forms of neurodegenerative disorders would be the
next step in increasing speciﬁcity to prion diseases.
3.3. Biomarkers in Blood. Blood is the ideal reservoir for
markers indicative of the progression of disease processes
in the body, samples are easy to obtain and noninvasive
to the patient, and as it circulates throughout the whole
body, is a repository for biomarkers of general health and
disease. Although no secondary transmission of the sporadic
or genetic forms of CJD has been reported, secondary
transmission of vCJD from “human-to-human” can occur
via blood transfusion. The infectious agent itself is present in
the blood in this instance probably following replication in
peripheral lymphoid tissue. An in vitro test to detect vCJD
prion contamination in human blood or blood products
is therefore one of the priorities for the development of
sensitive and speciﬁc tests. Diagnostic signatures of BSE have
been identiﬁed in serum of infected cattle by multivariate
analysis of infrared spectra, at a sensitivity of 85% and a
speciﬁcity of 90%, strongly supporting the hypothesis that
infection with prion agents leads to speciﬁc changes in the
molecular content of serum [69]. However, no predictive
tests for CJD or other prion disease have yet been validated
in blood, including detection of the prion speciﬁc biomarker
PrPSc.
A number of studies have identiﬁed diﬀerential abun-
dances of a handful of proteins in the blood of patients
with CJD. One study has shown an increase of the S-100ß
protein and another, an increase in cystatin C [70]. Another
recent study found elevated levels of heart fatty acid binding
protein (H-FABP) in the serum of patients with CJD [42].
Fatty acid binding proteins are located within the cell and are
responsible for the shuttling of fatty acids in the cytosol and
are released from the cell in response to cell damage [42].
However, again, high levels of this protein have also been
observed in acute myocardial infarctions, in stroke patients,
and Alzheimer’s patients, implying that this is not a speciﬁc
prion disease biomarker.
An early genomics study using diﬀerential display
reverse-transcriptase PCR (DDRT-PCR) to determine dif-
ferentially expressed genes in blood identiﬁed lower levels
of the erythroid diﬀerentiation-related factor (ERAF) in the
spleen, bone marrow and blood of scrapie infected mice
[71]. The same group also observed diﬀerential expression
of other erythroid-related genes (KEL, GYPA) in the spleens
of infected mice as a common feature of murine scrapie
[72]. However, these genes were found to be expressed at
highly variable levels between individuals, thus precluding
their usefulness as accurate markers for diagnosis.
Blood (serum and plasma) is one of the most diﬃcult
tissues to analyse using omic technologies. Blood is a
highly complex tissue that displays a huge dynamic range
of protein abundances challenging the identiﬁcation of the
less abundant species; these rare proteins and peptides
likely include the majority of disease speciﬁc biomarkers.Journal of Biomedicine and Biotechnology 9
Prefractionation steps are absolutely necessary to deplete the
mostabundantproteins[73].Themostcommonoftheseare
immunodepletion, used extensively for the speciﬁc removal
of high abundance proteins, based on the action of speciﬁc
antibodies. More recently, saturation protein binding to a
random peptide library has been proposed as an alternative
method [38]. Not surprisingly, given these diﬃculties and
the scarcity of samples from CJD patients and large animal
models, no proteomic screens for biomarkers of prion dis-
ease have been reported to date. Protein proﬁling of plasma
has been reported in a number of studies of Alzheimer’s
disease and these show some success as evidenced by
cross-study reproducibility and validation (albeit fairly low
sensitivity and speciﬁcity) in patient cohorts. In one study,
mass spectrometric analysis of the changes observed in
two-dimensional electrophoresis from the plasma of 50
Alzheimers patients and 50 matched controls identiﬁed a
number of proteins previously implicated in the disease
pathology. These included complement factor H (CFH)
precursorandalpha-2-macroglobulin(alpha-2M).Although
the speciﬁcity and sensitivity was fairly low, elevation of
CFH and alpha-2M was shown to be speciﬁc for Alzheimer’s
disease and to correlate with disease severity [38]. Two other
studies also identiﬁed these proteins as upregulated in the
plasma of Alzhiemers patients; given that prion diseases have
similar aetiologies it is likely that plasma may well be a rich
source for biomarkers to monitor disease progression, and
potentially for use in diagnosis [34, 35, 74].
Blood contains a number of circulating cells such as
lymphocytes, macrophages, dendritic cells and platelets.
Another approach in the search for biomarkers is to isolate
speciﬁc cell populations and use these as a basis for gene or
protein proﬁling studies. Targeting cells that may be involved
in prion replication may increase the chance of picking up
disease speciﬁc changes; however, no such studies have yet
been done. Circulating immune cells such as macrophages
and dendritic cells can carry infectious PrPSc and may
therefore traﬃc infectious prion agent around the body.
Macrophages have been found to contain PrPSc even in
the absence of FDCs, thus leading to the speculation that
they might serve as alternative sites of prion accumulation
and replication when there are no functional FDCs [56].
Dendritic cells are also mobile cells that can retain endocy-
tosed particles without degradation for long periods of time,
therefore ideal candidates for propagating prion proteins
throughout the body [75].
Activation of the innate immune system in the brain
is a general response during neurodegeneration, including
that induced by prions. Studies have identiﬁed inﬂamma-
tory genes that are signiﬁcantly induced or suppressed in
microglia isolated from CJD infected brains and these may
be a source for potential candidate markers. In one study
the CJD expression proﬁle obtained contrasted with that of
uninfected microglia exposed to prototypic inﬂammatory
stimuli such as lipopolysaccharide and IFN-gamma, as well
as PrP amyloid. Transcript proﬁles unique for microglia
and other myeloid cells involved in neurodegeneration
provide opportunities for the discovery of disease specﬁc
biomarkers [19]. A second study also describes the expres-
sion of a number of potentially neuroprotecive genes in
macrophages/microgliafromCJDinfectedpatients[76].The
serum levels of immunomarkers may reﬂect the inﬂamma-
tory process in the brain so that monitoring the levels of a
panel of these in the serum of infected individuals may track
the progress of the neurodegenerative process in patients.
Whether or not the inﬂammatory process is reﬂected in the
serum in prion diseases has not been investigated and is an
area for further work. However, a number of studies in other
diseases support this possibility including the identiﬁcation
of upregulated neuroinﬂammatory markers in the blood of
Parkinson’s aﬀected individuals [34, 35]a n das t u d yb yR a y
et al to identify plasma biomarkers of Alzheimer’s disease
usingantibodyarrays[48].Thesearra yswereusedtoidentify
18 plasma protein biomarkers that one able to discriminate
Alzheimer’sdiseasewith90%accuracy,themajorityofwhich
were immune related cytokines and growth factors.
3.4. Biomarkers in Urine. Urine is commonly used for diag-
nostic testing in many diﬀerent conditions and being some-
what less complex than serum is amenable to exploratory
biomarker analysis. Two recent studies have applied pro-
teomics for the identiﬁcation of prion-induced biomarkers.
In the ﬁrst study, the urine of infected cattle over the
time course of disease was examined using a combination
of 2D-DIGE and mass spectrometry analysis [37]. Four
classiﬁer proteins were identiﬁed, two of these proteins,
immunoglobulin Gamma-2 chain C region and clusterin
signiﬁcantly increased in abundance over time. Increase in
the abundance of immunoglobulins has also been reported
previously in the urine of scrapie-infected hamsters [77].
Levels of an isoform of clusterin were found to predict with
100%accuracyduringinfectionwithBSE,however,thestudy
size was extremely small and limited to a single sample group
and so requires validation. Clusterin is a multifunctional
glycoprotein found ubiquitously expressed throughout the
body and is abundant in astrocytes, CSF, and blood plasma
[39, 78]. Its expression has been found to increase in the
brains of prion infected mice as well as in other neurode-
generative diseases, and on insult to the brain. A recently
reported identiﬁed clusterin as a blood borne biomarker
following plasma proﬁling in Huntington’s disease patients
and additionally saw its upregulation in the CSF of aﬀected
individuals [79]. These studies suggest clusterin could have
general utility as an inﬂammatory associated marker for
multiple conditions including neurodegeneration.
In the second study, urinary alpha1-antichymotrypsin
was found to be dramatically increased in urine of patients
suﬀering from sporadic Creutzfeldt-Jakob disease and a
number of other animal models of prion disease [36].
Alpha1-antichymotrypsin, like clusterin, has been identiﬁed
as a potential disease marker in many disparate diseases
includingtheresponsetorenalandotherinjuries,anddereg-
ulation of expression in many cancers and is therefore not
speciﬁc to TSEs. It is likely that as both clusterin and alpha1-
antichymotrypsin levels are highly responsive to multiple
diseases and trauma that the levels in a normal population
would preclude utility as a diagnostic marker. However, as10 Journal of Biomedicine and Biotechnology
levels of both clusterin and alpha1-antichymotrypsin were
reported to increase incrementally during the course of
disease, this type of marker could potentially be used to
monitor the progress of degeneration in individuals during
treatment.
3.5. Exosomes. Exosomes have been investigated for their
value as “repositories” for biomarker detection. Exosomes
are small (50–90nm) microvesicles that originate in the cell
and following release are thought to be able to migrate and
interact with or on other cells [80]. They are often released
by cells undergoing stress or other stimuli and may there-
fore act as carriers of potential biomarkers. Additionally,
exosomes are easily isolated from multiple biological ﬂuids
and have a much less complex protein component than
whole blood, serum, CSF or urine; during the formation
of intraluminal vesicles in exosomes extensive sorting of
proteins and lipids occurs at the membrane of endosomes
which results in them containing a speciﬁc group of proteins
[80]. Recently the presence of both PrPC [81]a n dP r P Sc
[82]onexosomeshasbeendemonstrated.Inprioninfection,
exosomes may be ideal candidates for biomarker discovery
as they have been reported to be released from several
cell types that are involved in prion infection, including
intestinal epithelial cells, neurons, neuroglial cells, and
DCs.
PrPSc is associated with exosomes from neuroglial and
epithelial cells and these may provide a means of cell-
to-cell transfer of infectious prions [82]. FDCs which are
actively involved in peripheral prion replication release
signiﬁcant numbers of exosomes on stimulation and it is
possible that these are involved in the extracellular transport
of PrPSc to nerve endings, although the mechanism by
which prions travel from FDCs to the nervous system is
presently unknown. It has, however, been shown that the
topographical location between FDCs and nerve endings
plays a key role in determining the eﬃciency of neu-
roinvasion; the process is accelerated when FDCs are in
closer contact with the nerve endings [83]. As exosomes
in human plasma may have a multitude of cellular origins
including release from human platelets, epithelial cells and
hemopoetic cells such as mast cells we believe they could be
both a source of biomarkers for early detection of PrPSc in
peripheral infection or for the identiﬁcation of biomarkers
speciﬁc to prion replication. Alternatively, they may be
reservoirs of inﬂammation- or stress-related biomarkers that
could be detected in plasma, CSF or urine. Although these
avenues have yet to be explored in prion diseases, other
studies to identify exosomal biomarkers provide proof-of-
principle, such as the identiﬁcation of Fetuin-A as a potential
biomarker from urine in patients with acute kidney injuries
and glioblastoma [84, 85].
4.FuturePerspectivesinPrion
Biomarker Research
Techniques for protein proﬁling are rapidly evolving as
are techniques for rapid genome scale sequencing for gene
expression proﬁling. Other novel methodologies can be
applied to the fractionation and isolation of pertinent cell
types from which to isolate more speciﬁc markers of prion
disease and neurodegenerative processes. One technique that
shows promise in this regard is laser-capture microdissec-
tion (LCM) capable of isolating individual cells from cut
tissue sections, thus allowing identiﬁcation of RNA and
protein changes speciﬁcally in prion-replicating cells. These
biomarkersmaywellbetooscarcetopickuponexamination
of whole tissues or body ﬂuids. It is a useful tool for either
markers of peripheral infection in cells from the spleen, gut
mucosa, and lymphoid tissue such as tonsils, or to identify
prion-replication associated markers, or neuronal health
related markers in brain tissues which may well translate to
markers in CSF or blood. So far LCM biomarker research on
prion diseases and other neurodegenerative disorders is in its
infancy but is a promising area for future research.
A burgeoning area for biomarker research is the iden-
tiﬁcation of dysregulated small noncoding RNAs, especially
the recently identiﬁed family of microRNAs (miRNAs)
which are involved in post-transcriptional regulation of
gene expression in both plants and animals [86]. These
short RNAs have been determined to have regulatory roles
that are vital to many cellular processes and appear to be
particularly active in controlling complex functions in the
nervous system such as neurodevelopment and neuronal
function. Recently, compelling evidence for the involvement
of microRNAs (miRNAs) in neurodegenerative diseases
including Alzheimer’s, Parkinson’s and prion diseases, has
been published [87–89]. Indeed two miRNAs exhibiting
increasedexpressioninthebrainsofrodentmodelsofscrapie
were similarly upregulated in the brains of BSE infected
macaques illustrating the potential for consistency across
species [90]. The potential of miRNAs as biomarkers for
diagnosis and prognosis has also been endorsed by studies
showing that expression of miRNAs in various cancers
can be highly speciﬁc and discriminatory proﬁles between
diseased and non-diseased tissues can be readily identiﬁed
[91].
5. Conclusion
Signiﬁcant advances in recent years in technologies for
high-throughput sequencing and proteomics mean that the
future is bright for biomarker discovery in relation to
prion diseases. Of particular note are the ability to obtain
transcriptional proﬁles from homogeneous cell populations
at diﬀerent stages of disease, advances in prefractionation
methods for proteomic studies, and the possibility of high-
throughput proteomics to identify ever increasing numbers
of individual proteins from a single sample. However, a
number of unique hurdles and pitfalls remain in relation
to prion diseases; these include the very small number of
clinical cases for validatory studies, the long incubation
period, and the variability of pathogenesis between strains
and routes of infection. It is this heterogeneity among prion
disease phenotypes that requires careful choice of tissues
and time points to use as starting materials for biomarkerJournal of Biomedicine and Biotechnology 11
discovery.Giventhesefactorsitmaywellbeimpossibleto,for
example, identify a single preclinical biomarker congruent
to the diagnosis of all prion diseases. Conversely, similarities
betweenmolecularmechanismsleadingtodamageanddeath
of neurons in multiple degenerative conditions may allow
the broad utility of biomarkers to track disease progression
or to predict the onset of disease between prion and other
neurodegenerative conditions. Another factor of note that
contributes to the relatively slow progress of research in
this area relates to the physical properties of the agent
itself. The resistance of prions to conventional chemical
and physical procedures designed to inactivate viruses and
bacteria means that infected tissues must be analysed under
biocontainment conditions. Analysis equipment must in
many instances be dedicated to TSE biomarker discovery
following contamination with potentially infectious prions.
These issues often preclude the use of the most up-to-date
techniques that rely on expensive, often core-facility-based,
apparatus.
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